Multiple Myeloma · Active Clinical Trials
As of 2026-09-04, the full China registry snapshot contains 70 active multiple myeloma interventional trials across 31 provincial-level regions and 338 China study centres, see landscape index. The list below provides peer-reviewed published English translations and can be filtered by modality, target, phase, and province.
Notice for International Patients
These records are provided for research-information purposes. An English summary does not mean that the clinical trial accepts international patients. Eligibility, language requirements, residence requirements and long-term follow-up must be confirmed directly with the clinical trial team. Original registry filings remain in Chinese. For a non-trial route, see independent guide to CAR-T in China.
Trial Decision Guides
All trial FAQsNotice for Patients on Stable Therapy:If your current regimen is effective, do not discontinue standard treatment. Clinical trial matching is recommended upon documented disease progression.
A Two-Stage, Randomized, Multicenter, Controlled, Open-Label, Phase III Study Comparing Iberdomide Maintenance Therapy with Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)
Locations & Centers
Peking University People's Hospital、Tongji Medical College of Huazhong University of Science and Technology、Qilu Hospital of Shandong University 等 37 家
Target / Modality
Oral small-molecule "molecular glue" degrader (next-generation Cereblon E3 ligase modulator [CELMoD])